text_combined: samia saad samiasaadgmailcom picked textplain multipartalternative research background paper good practice pharmaceutical industry uk government policies access medicines background 2005 uk department international development dfid uk department health dh uk department trade industry 1 11b8e36720abeba6__ftn1 published policy paper set framework provide guidance pharmaceutical companies best practices increasing access medicines developing countries211b8e36720abeba6__ftn2the paper also set complementary uk government commitments since date many developments company government policies generally global environment access uk donor governments substantially increased commitments organisations global fund fight aids tb malaria311b8e36720abeba6__ftn3and access key medicines particular antiretrovirals expanded significantly initiatives also taken stimulate innovation advanced market commitment411b8e36720abeba6__ftn4for pneumoccocal vaccines governments companies worked together publicprivate partnerships develop new drugs vaccines needed developing countries many companies maintained developed differential pricing offers developing countries licensed technologies freely developing country producers still much governments companies need help improve access medicines research consultation objectives uk governments 2005 framework suggested uk report progress later date including relation impact framework uk government pharmaceutical companies usefulness companies stakeholders key outstanding issues new areas work end dfid contracted two consultants emma back samia saad conduct research collect data include thorough review practices policies outlined 2005 framework relating affordability research development impact developing countries reporting verification review impact 2005 framework uk government industry policy actions review process developing implementing 2005 framework assessment alongside processes adopted similar documents example developed industry investors oxfam access medicines index un special rapporteur right health gathering material relating performance government companies policies noting particular examples good practice consultation necessary future policies plans industry representatives already established industry working group supported association british pharmaceutical industries abpi identification key issues need addressed companies government light current circumstances promote better access medicines including interviews key informants companies government stakeholders including civil society focus research researchbased industry also consider role generic industry good practice principles might apply activities consultation also include technical agencies world health organization third party providers facilitators access medicines programmes relevant purpose research produce background paper documenting developments since 2005 assessing progress paper form basis subsequent revision uks 2005 good practice framework timelines 1 desk based research conducted july august 2008 2 consultation necessary industry uk government departments relevant stakeholders conducted 119 september 2008 3 draft research report circulated industry others early october 2008 4 consultation discuss draft research report conducted midoctober 2008 outputs based reviews consultations outlined background report produced inform subsequent edition uks good practice framework development managed dfid collaboration berr dh intellectual property office ipo consultants background report set developments industry government since 2005 relation aspirations commitments made 2005 uk government paper contain 1 factual material policies pursued industry government relation research pricing patenting licensing areas covered 2005 framework 2 qualitative assessment progress made since 2005 industry government implementing policies access medicines identifying key areas good progress made areas room improvement 3 assessment impact 2005 framework paper specifically process employed develop track implementation stimulating progress comments comments invited interested parties aid consultants work comments concise 2 pages highlight particular issues respondents believe consultants take account comments received 22 august 2008 please address comments emma back emmaback1hotmailcom samia saad samiasaadgmailcom 1 11b8e36720abeba6__ftnref1 department business enterprise regulatory reform berr 2 11b8e36720abeba6__ftnref2 increasing peoples access essential medicines developing countries framework good practice pharmaceutical industry march 2005 httpwwwdfidgovukpubsfilespharmframeworkpdf 3 11b8e36720abeba6__ftnref3 pledges contributions global fund httpwwwtheglobalfundorgenfunds_raisedpledges 4 11b8e36720abeba6__ftnref4 advance market commitments vaccines httpwwwvaccineamcorg samia saad consultant health pharmaceuticals policy uk mobile 0044 7789 432838 email samiasaadgmailcom _______________________________________________ iphealth mailing list iphealthlistsessentialorg httplistsessentialorgmailmanlistinfoiphealth mon 04 aug 2008 160703 0100 iphealth research dfids good practice pharmaceutical industry